With U.S. funding for science at risk, a longtime advocate sees ‘light at the end of the tunnel’ in Washington.

Last November, in the days following Donald Trump’s election, leaders at the National Institutes of Health began discussing ...

Eli Lilly said it would raise drug prices in Europe to "make them lower" in U.S., though the actual impact on most patients ...

A modified CD40 antibody shrank or eliminated tumors in six of 12 metastatic cancer patients without the side effects that ...

A handful of drug companies have formed a group to present lawmakers with research on the negative impacts of Medicare drug ...

Keeping blood pressure below 120/80 lowers risk of dementia, as well as heart and kidney disease, new guidelines say.

Kornbluth learned lessons from the Duke cancer fraud case that “have powerfully shaped my approach to leadership ever since.” ...

A recent U.S. warning on use of 'march-in' rights against Harvard University seems like distant threat for pharma. Here's why ...

This is the web edition of D.C. Diagnosis, STAT's twice-weekly newsletter about the politics and policy of health and ...

Inner speech — the internal monologue in your brain as you think about what to say — can be decoded by computers and might ...

For more on Prasad’s return, go here; for a “Matt’s Take” on Prasad, go here; for the latest on investors’ attitudes toward ...

Can Boston stay on top in biotech? Find out on Sept 17, 6-9 p.m. EDT to explore talent shifts, funding, and Boston’s future.